In patients with COVID‐19, a severity‐dependent decrease is found in activation and maturation markers including HLA‐DR and CD86 as well as an increase in the expression of the regulatory molecule PD‐L1 on both monocytes and DCs, especially in severe COVID‐19 [4, 21, 27, 65, 68]. The gene discussed is CD86; the disease is COVID-19.